- 期刊
- OpenAccess
Management of Loose, Frequent Stools and Fecal Incontinence in a Chronic Mesenteric Ischemia Patient with Oral Serum-derived Bovine Immunoglobulin
並列摘要
AIM: Chronic diarrhea with fecal incontinence (FI) is a severe, underreported, and intractable problem in many patients for which limited pharmaceutical options exist. METHODS: A retrospective case history was collected after the administration of a prescription medical food composed of serum-derived bovine immunoglobulin/ protein isolate (SBI) at 5 g once daily in a patient with chronic mesenteric ischemia (CMI) for chronic loose, frequent, and urgent stools. The patient was an 84-year-old white male with a 20-year history of progressively worsening chronic diarrhea with six to eight watery stools per day (Bristol Stool Form Scale, Type 7), urgency, nocturnal diarrhea, FI, and postprandial abdominal discomfort before administration of SBI. RESULTS: After four weeks of SBI administration, the patient had two to three soft, semi-formed stools (Bristol Stool Form Scale, Types 4 and 5) per day with no nocturnal diarrhea, urgency, or FI, as well as full resolution of abdominal discomfort. In addition, the patient expressed an enhanced quality of life (QoL): able to travel, attend social events, and perform tasks not possible before therapy. CONCLUSION: This case underscores how a safe, nutritional therapy may offer a new modality for physicians to address chronic loose, frequent stools with FI in patients with CMI in this difficult to manage gastrointestinal population.
延伸閱讀
- Baldane, S., Sivgin, S., Alkan, T. S., Kurnaz, F., Pala, C., Keklik, M., Karaman, A., & Kaynar, L. (2012). An Atypical Presentation of Brucellosis in a Patient with Isolated Thrombocytopenia Complicated with Upper Gastrointestinal Tract Bleeding. Case Reports in Medicine, 2012(), 203-206-151. https://doi.org/10.1155/2012/473784
- Wang, C. J., & Wang, P. H. (2016). Disseminated Mycobacterium kansasii Infection in a Non-Human Immunosuppressive Virus-Infected Patient without Immunosuppressive Therapy. 胸腔醫學, 31(3), 169-175. https://www.airitilibrary.com/Article/Detail?DocID=10239855-201606-201605240007-201605240007-169-175
- Yu, L., Yang, X., Xia, L., Zhong, J., Ge, W., Wu, J., Liu, H., Liu, F., & Liu, Z. (2015). Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa. Mediators of Inflammation, 2015(), 159-167-413. https://doi.org/10.1155/2015/793764
- SCOTT, L. C., WHITE, J. D., REID, R., & COWIE, F. (2005). Management of skin toxicity related to the use of imatinib mesylate (STI571, Glivec^(TM)) for advanced stage gastrointestinal stromal tumours. Sarcoma, 2005(), 157-160. https://doi.org/10.1080/13577140500349717
- Wei, C. Y., Hsu, Y. H., Chou, W. J., Lee, C. P., & Tsao, W. L. (2004). Molecular and Histopathologic Evidence for Systemic Infection by Mycobacterium Bovis in a Patient with Tuberculous Enteritis, Peritonitis, and Meningitis: A Case Report. The Kaohsiung Journal of Medical Sciences, 20(6), 302-307. https://www.airitilibrary.com/Article/Detail?DocID=02575655-200406-20-6-302-307-a